Live talk
Join us Thursday, January 26, at 3:00 pm PST, for a lively discussion on issues affecting pituitary medicine and patients. The recorded session will be available on-demand following our live program.
Read more about Live Talk here – Listen to our past sessions on demand.
Articles of note for people dealing with pituitary disease and related conditions.
Join a drug trial. Find out how. Here’s a partial list of studies.
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Articles of note for people connected to pituitary disease
Our briefing today covers articles on costs and access to therapies, sugar and artificial sweeteners, surprising news on where we are finding endocrine disruptive chemicals, an amazing discovery about a new brain layer, and a bunch of information on Cannabidiol (CBD) focusing on what we know and what we don't. This is great info you don't want to miss. Read on!
The social media conundrum: a commentary
The constant changes in how social media operate make it challenging to understand how to use them effectively to spread helpful information. So, even though you may be following PWN, you may not get all our articles and podcasts in your feed.
News In Brief
Recordati Rare Diseases Introduces Cushing’s Conversations, a new support program for people who have been prescribed ISTURISA®. Read more
Crinetics Pharmaceuticals announces enrollment is complete in the placebo-controlled Phase 3 PATHFNDR-1 study evaluating the safety and efficacy of once-daily oral #paltusotine in #acromegaly patients. Read more
Amryt Pharma relaunches its patient-facing website for Mycapssa
Corcept Therapeutics announces new communication materials for Phase 3 Trial of Relacolirant in patients with Cushing’s syndrome. Click here to learn more and see if you qualify.
Content for physicians and healthcare professionals.
The latest from pharmaceutical companies and related organizations
Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Today we present an excellent discussion with Dr. Alan Krasner, Chief Medical Officer for Crinetics Pharmaceuticals. Dr. Krasner speaks to PWN about two very important drugs currently under development. Learn about what is coming, the timelines, potential new therapies, and approaches in acromegaly, Cushing's, and hyperinsulinism.
The ongoing debates and nomenclature change and reclassification are apparently over, and adenomas and now referred to as Pit-Net's (pituitary neuroendocrine tumors). Is this good, bad, or indifferent? These are complicated matters, so to shed some more light on the subject, we've invited some experts to discuss them.
In today's podcasts, Dr. Blevins talks about the genesis of pseudo Cushing's syndrome and illustrates a fascinating case of pseudo Cushing's syndrome due to alcohol ingestion.
Subscribe & Listen
Apple Podcasts
Spotify
Amazon Music
Google PodcastsLive Talk on Demand
Events
Pituitary Patient Education Day. Learn More and register.
If you missed the live event, here is the recorded session with critical information on navigating Medicare.
